National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-Cho, Obihiro, Hokkaido 080-8555, Japan; Department of Internal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-Cho, Obihiro, Hokkaido 080-8555, Japan; Department of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
Parasitol Int. 2022 Oct;90:102596. doi: 10.1016/j.parint.2022.102596. Epub 2022 May 6.
In the current investigation, the effect of ascorbic acid on the in vitro growth of several piroplasm including Babesia bovis (Bartonella bovis), Baconia bigemina, B. caballi, and Theileria equi (T. equi), as well as against Brucella microti in mice was assessed. The antipiroplasm efficacy of ascorbic acid in vitro and in vivo was assessed using a fluorescence-based SYBR Green I test. Using atom pair fingerprint (APfp), we investigated the structural similarity between ascorbic acid and the commonly used antibabesial medicines, diminazene aceturate (DA) and imidocarb dipropionate (ID). In vitro cultures of B. bovis and T. equi were utilized to determine the ascorbic acid and DA interaction using the Chou-Talalay method. Ascorbic acid inhibited B. bovis, B. bigemina, T. equi, and B. caballi growth in vitro in a dose-dependent manner. The APfp results revealed that ascorbic acid and DA have a maximum structural similarity (MSS). On a T. equi culture in vitro, ascorbic acid showed a synergistic interaction with DA, with a combination index of 0.28. B. microti growth was decreased by 41% in vivo using ascorbic acid combined with a very low dosage of DA (6.25 mg kg). The results imply that ascorbic acid /DA could be a viable combination therapy for the treatment of T. equi and that it could be utilized to overcome the resistance of Babesia parasites to full doses of the regularly used antibabesial medication, DA.
在当前的研究中，评估了抗坏血酸对几种梨形虫（包括牛巴贝斯虫（Bartonella bovis）、双芽巴贝斯虫、马巴贝斯虫和马媾疫锥虫（T. equi））以及在小鼠体内对布鲁氏菌微小动物的体外生长的影响。使用基于荧光的 SYBR Green I 测试评估抗坏血酸的抗梨形虫功效。使用原子对指纹（APfp），我们研究了抗坏血酸与常用抗巴贝斯虫药物（延胡索酸乙酰苯胺（DA）和咪唑苯并二氮卓二丙酸盐（ID））之间的结构相似性。使用 Chou-Talalay 方法，在 B. bovis 和 T. equi 的体外培养物中确定抗坏血酸和 DA 的相互作用。抗坏血酸以剂量依赖性方式抑制 B. bovis、B. bigemina、T. equi 和 B. caballi 的体外生长。APfp 结果表明，抗坏血酸和 DA 具有最大结构相似性（MSS）。在体外 T. equi 培养物中，抗坏血酸与 DA 表现出协同相互作用，组合指数为 0.28。体内联合使用非常低剂量的 DA（6.25mg/kg）可使 B. microti 的生长减少 41%。结果表明，抗坏血酸/DA 可能是治疗 T. equi 的一种可行的联合治疗方法，并且可以用来克服巴贝斯虫寄生虫对常用抗巴贝斯虫药物 DA 的全剂量的耐药性。
Zotero 插件